Search Results 261-270 of 8809 for substance P

  1. Translational Neuromuscular Disease Research Laboratory - Biological mechanisms of peripheral neuropathy

    Mayo Clinic's Translational Neuromuscular Disease Research Lab led by Nathan P. Staff, M.D., Ph.D., studies the biological mechanisms that cause peripheral ...

  2. Macitentan in Pulmonary.

  3. Foamy urine: What does it mean? - Mayo Clinic

    Persistently foamy urine can be a sign of protein in your urine (proteinuria) and could be an indicator of kidney disease.

  4. Publications - Paras H. Shah, M.D. - Mayo Clinic

    ... P, Pradere B, Shah P, Boorjian SA, Moschini M, Radziszewski P. Comparative Assessment of Chemotherapy Followed by Consolidative Radical Cystectomy Versus ...

  5. Progressive supranuclear palsy - Doctors and departments - Mayo Clinic

    Displaying 1-1 out of 1 doctors available. Last Name Initial: P,P. Ronald C. Petersen, M.D., Ph.D. Neurologist. Rochester, MN ...

  6. Publications - Mark D. Williams, M.D. - Mayo Clinic

    ... P, Leung JG, Ozerdem A, Savitz ST, Williams MD ... Treatment of Substance Use Disorders With a ... Raney L, Williams M, Gibson P, Salter T.

  7. C-reactive protein test - Mayo Clinic

    This simple blood test measures inflammation in the body. The results help diagnose infection and, sometimes, predict the risk of heart attack.

  8. Benzoyl peroxide and clindamycin (topical application route) - Side effects & dosage - Mayo Clinic

    Substance Name. Clindamycin. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the ...

  9. Chronic traumatic encephalopathy - Symptoms and causes - Mayo Clinic

    Emotional instability. Substance misuse. Suicidal thoughts or behavior. Movement symptoms. Trouble with walking and with balance. Shaking, slow movement and ...

  10. Publications - Pedro A. Reck dos Santos, M.D. - Mayo Clinic

    ... P. The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients ...